Enorama Pharma AB (OSTO:ERMA) Moat Score: 0/10 (As of Jul. 11, 2026)


OSTO:ERMA Enorama Pharma AB OSTO:ERMA
28 GF Score
Price kr0.26
GF Value kr0.41
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Enorama Pharma AB Moat Score?

Enorama Pharma AB has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Enorama Pharma AB has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Enorama Pharma AB might have No Moat - No discernible moat.

Enorama Pharma AB  (OSTO:ERMA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Enorama Pharma AB Moat Score Related Terms

OSTO:ERMA
28GF Score
Enorama Pharma AB OSTO:ERMA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Enorama Pharma AB (OSTO:ERMA) Overvalued in 2026?

Based on GuruFocus' analysis, Enorama Pharma AB stock appears to be undervalued. The current stock price of kr0.26 is trading 37.8% below its estimated GF Value™ of kr0.41. GuruFocus considers Enorama Pharma AB to be Possible Value Trap.

Key valuation signals for OSTO:ERMA:

  • Moat Score: 0
  • GF Value™: kr0.41 vs. price of kr0.26 (37.8% below fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the OSTO:ERMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enorama Pharma AB Business Description

Address Vastra Varvsgatan 19, Malmo, SWE, SE-211 77
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.
28GF Score

Get the complete analysis for OSTO:ERMA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.26
Price
kr0.41
GF Value